Revisión por temas de las últimas publicaciones en las que han participado miembros del grupo

Archivado en Noticias

Colitis ulcerosa

1. Systematic review and network meta-analysis of treatment for moderate-to-severe ulcerative colitis.

Trigo-Vicente C, Gimeno-Ballester V, García-López S, López-Del Val A.
Int J Clin Pharm. 2018 Dec;40(6):1411-1419.
PMID: 30478492

2. Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus.

Danese S, Allez M, van Bodegraven AA, Dotan I, Gisbert JP, Hart A, Lakatos PL, et al.
Dig Dis. 2019 Feb 6:1-18 (Free Article)
PMID: 30726845

3. Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis.

Taxonera C, Iborra M, Bosca-Watts MM, Rubio S, Nantes Ó, Higuera R, et al.
Curr Med Res Opin. 2019 Feb 5:1.
PMID: 30722703

Enfermedad de Crohn

1. Usefulness of Thiopurine Monotherapy for Crohn’s Disease in the Era of Biologics: A Long-Term Single-Center Experience.

Suárez Ferrer C, González-Lama Y, González-Partida I, Calvo Moya M, Vera Mendoza I, Matallana Royo V, et al.
Dig Dis Sci. 2018 Dec 12.
PMID: 30542812

2. The role of intravenous Contrast Agent in the Sonographic Assessment of Crohn’s Disease Activity: Is Contrast Agent Injection Necessary?
Ripollés T, Martínez-Pérez MJ, Paredes JM, Vizuete J, Martin G.
J Crohns Colitis. 2018 Dec 8.
PMID: 30535070

3. Short Disease Duration Does Not Always Indicate Early Crohn’s Disease.
Rodríguez-Lago I, Barreiro-de Acosta M.
Clin Gastroenterol Hepatol. 2019 Jan 18.
PMID: 30664948

4. Intravenous Contrast-Enhanced Ultrasound for Assessing and Grading Postoperative Recurrence of Crohn’s Disease.
Martínez MJ, Ripollés T, Paredes JM, Moreno-Osset E, Pazos JM, Blanc E.
Dig Dis Sci. 2019 Jan 2.
PMID: 30604372

5. Secondary Haemophagocytic Syndrome and Overlapping Immune Reconstitution Syndrome: Life-Threatening Complications of Anti-TNF-α Treatment for Crohn’s Disease.
Sáez-González E, Salavert M, Cerrillo E, Moret I, Iborra M, Nos P, Beltrán B.
Am J Gastroenterol. 2019 Jan;114(1):177-179.
PMID: 30413818

Tratamiento en EII

1. Iron Treatment May Be Difficult in Inflammatory Diseases: Inflammatory Bowel Disease as a Paradigm.
Gargallo-Puyuelo CJ, Alfambra E, García-Erce JA, Gomollon F. (FREE ARTICLE)
Nutrients. 2018 Dec 11;10(12). pii: E1959.
PMID: 30544934

Endoscopia y EII

1. Retrograde single-balloon enteroscopy for the removal of a mollusc shell retained in the ileum of a patient with active Crohn’s disease.
Martínez Lozano H, Nogales Rincon O, Navarrete Marín C, Conthe Alonso A, García Lledó J, Menchén Viso L, Marín-Jiménez I.
Endoscopy. 2019 Jan;51(1):E14-E15.
PMID: 30406633

2. Role of interventional inflammatory bowel disease in the era of biologic therapy: a position statement from the Global Interventional IBD Group.
Shen B, Kochhar G, Navaneethan U, Liu X, Farraye FA, Gonzalez-Lama Y, et al. Global Interventional Inflammatory Bowel Disease Group.
Gastrointest Endosc. 2019 Feb;89(2):215-237
PMID: 30365985

3. Evaluation of a new pan-enteric video capsule endoscopy system in patients with suspected or established inflammatory bowel disease – feasibility study.
Eliakim R, Spada C, Lapidus A, Eyal I, Pecere S, Fernández-Urién I, et al. (Free)
Endosc Int Open. 2018 Oct;6(10):E1235-E1246.
PMID: 30302381

Percepciones del paciente. Telemedicina. Impacto y calidad de vida

1. A Web-Based Telemanagement System for Patients With Complex Inflammatory Bowel Disease: Protocol for a Randomized Controlled Clinical Trial.
Aguas M, Del Hoyo J, Faubel R, Muñoz D, Domínguez D, Bastida G, et al. (FREE)
JMIR Res Protoc. 2018 Dec 21;7(12):e190.
PMID: 30578197

2. Healthcare Experience and their Relationship with Demographic, Disease and Healthcare-Related Variables: A Cross-Sectional Survey of Patients with Chronic Diseases Using the IEXPAC Scale.
Orozco-Beltrán D, de Toro J, Galindo MJ, Marín-Jiménez I, Casellas F, Fuster-RuizdeApodaca MJ, et al.
Patient. 2018 Nov 15.
PMID: 30430456

3. Prevalence and Factors Associated with Fatigue in Patients with Inflammatory Bowel Disease: A Multicenter Study.
Chavarría C, Casanova MJ, Chaparro M, Barreiro-de Acosta M, Ezquiaga E, Bujanda L, et al.
J Crohns Colitis. 2019 Feb 5
PMID: 30721954

4. ‘Quality of Care’ Standards in Inflammatory Bowel Disease: A Systematic Review.
Fiorino G, Allocca M, Chaparro M, Coenen S, Fidalgo C, Younge L, Gisbert JP.
J Crohns Colitis. 2019 Jan 1;13(1):127-137.
PMID: 30423033

5. Pregnancy and Inflammatory Bowel Disease: A Long Way to Go.
Chaparro M, Gisbert JP
Am J Gastroenterol 2018; Dec 113 (12): 1903-1904
PMID: 30356179

Predicción de recurrencia, respuesta y progresión

1. Withdrawal of Azathioprine in Inflammatory Bowel Disease Patients Who Sustain Remission: New Risk Factors for Relapse.
Iborra M, Herreras J, Boscá-Watts MM, Cortés X, Trejo G, Cerrillo E, Hervás D, Mínguez M, Beltrán B, Nos P.
Dig Dis Sci. 2019 Jan 2.
PMID: 30604371

2. Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease.
Guerra Veloz MF, Argüelles-Arias F, Castro Laria L, Maldonado Pérez B, Benítez Roldan A, et al. (Free article)
World J Gastroenterol. 2018 Dec 14;24(46):5288-5296.
PMID: 30581277

3. Screening for colorectal cancer in patients with inflammatory bowel disease. Should we already perform chromoendoscopy in all our patients? (FREE)
Huguet JM, Suárez P, Ferrer-Barceló L, Iranzo I, Sempere J.
World J Gastrointest Endosc. 2018 Nov 16;10(11):322-325.
PMID: 30487942

4. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
Chaparro M, Barreiro-de Acosta M, Echarri A, Almendros R, Barrio J, Llao J, et al.
Dig Dis Sci. 2018 Nov 13.
PMID: 30426297

Genética, inmunología, proteómica

1. Characteristics of Inflammatory Bowel Disease in patients of Roma/Gypsy ethnicity. A case-control study.
Cabré E, Mañosa M, Marín I, Martín-Mateos R, Iglesias-Flores E, Barreiro-de-Acosta M, Nos P, Busquets D, Menchén LA, López-Sanromán A, Domènech E.
Dig Liver Dis. 2018 Dec 19
PMID: 30606697

2. Modulation of faecal metagenome in Crohn’s disease: Role of microRNAs as biomarkers.
Rojas-Feria M, Romero-García T, Fernández Caballero-Rico JÁ, Pastor Ramírez H, Avilés-Recio M, Castro-Fernandez M, et al. (FREE)
World J Gastroenterol. 2018 Dec 14;24(46):5223-5233.
PMID: 30581271

 

 

archivado en Noticias | publicado el 13 de febrero de 2019 | última actualización: 13 de febrero de 2019 10:49
Formación EII
Canal de GETECCU en YouTube
Base de datos ENEIDA
Nuestros patrocinadores|lea nuestra política de patrocinio